D20 - Optimizing Cardiometabolic Outcomes in CKD Care through DCES-Led Systems Change

Sunday, August 10, 2025

1:30 PM – 2:15 PM MT

CE/CME Hours: .75 CE

Pharmacology Hours: 0.0 CE

Primary Presenter(s)

Andrew Bzowyckyj, PharmD, BCPS, CDCES, FADCES, FAPhA (he/him/his)

Senior Scientific Director, Learning Consultant
National Kidney Foundation
Beaverton, Oregon

Disclosure(s): No financial relationships to disclose

Co-Presenter(s)

MS

Megan Schultz, MPH

Population Health Partnership Director
National Kidney Foundation
Saint Louis, Missouri

Disclosure(s): No financial relationships to disclose
EM

Elizabeth Montgomery, BS

National VP, Clinical Practice Innovation and Population Health
National Kidney Foundation
New York, New York

Disclosure(s): No financial relationships to disclose

Chronic kidney disease (CKD) impacts 1 in 7 U.S. adults, yet 90% of adults remain undiagnosed. CKD is a disease multiplier and people living with CKD and diabetes generate roughly 208% greater medical costs compared to people without CKD, and costs rise with additional co-morbidities. Annual testing for CKD among people with diabetes is a HEDIS quality measure, with national performance sitting under 45%, leaving money on the table for many institutions. The DCES is well-positioned to improve CKD testing, diagnosis, and management to elevate the quality of care and reduce costs. This session will present an evidence-based strategy for DCES led systems and practice changes.

Disclosure(s):

Andrew Bzowyckyj, PharmD, BCPS, CDCES, FADCES, FAPhA: No financial relationships to disclose

Megan Schultz, MPH: No financial relationships to disclose

Elizabeth Montgomery, BS: No financial relationships to disclose